-
Product Insights
New![]()
Net Present Value Model: Novo Nordisk AS’s FDC Sema – OW GIP
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Semaglutide + GIP Analogue) in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Semaglutide + GIP Analogue) in Type 2 Diabetes Drug Details: NN-9389 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Obstructive Sleep Apnea
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Obstructive Sleep Apnea Drug Details: Tirzepatide (Mounjaro, Zepbound) is a 39-amino-acid modified peptide...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure) Drug Details: Tirzepatide (Mounjaro, Zepbound) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Obesity Drug Details: Tirzepatide (Mounjaro) is a 39-amino-acid modified peptide based on the...
-
Product Insights
New![]()
Net Present Value Model: Novo Nordisk AS’s NNC0519-0130
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Novo Nordisk AS's NNC0519-0130 Drug Details: NNC0519-0130 is under development for the treatment of obesity and type 2 diabetes. It is administered through oral...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2735 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Obesity Drug Details: VK-2735 is under development for the treatment of obesity and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Retatrutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Retatrutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Drug Details: Retatrutide (LY-3437943) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Retatrutide in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Retatrutide in Obesity Drug Details: Retatrutide (LY-3437943) is under development for the treatment of type...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.